Oppenheimer Oppenheimer Downgrades Invitae to Perform Rating Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares." M&A Deals in MDx/Omics Research Tools Space Fall 13 Percent in 2020 Premium Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags. Oppenheimer Initiates Coverage of Bionano Genomics at Outperform The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis. Bionano Genomics to Publicly Offer Securities, Amends Loan Agreement The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal. Bionano Genomics Prices $18M Public Offering Shares of firm fell 47 percent on the news it will sell 20.9 million common shares along with warrants to purchase up to the same number of shares. Jan 22, 2013 Analysts Speculate on Potential Life Technologies Sale Sep 4, 2012 Oppenheimer Bullish on Life Tech's Ion Proton Instrument as Anticipated Launch Nears Jan 13, 2012 Bank Ups Revenue Estimate on Sequenom Oct 5, 2011 Oppenheimer Starts Coverage of Genomic Health, Thermo Fisher Scientific, Fluidigm Sep 22, 2011 Oppenheimer Lowers EPS, Revenue Estimates for PacBio Following Layoffs Aug 26, 2011 Oppenheimer Analyst Calls Life Tech Shares Undervalued, Reiterates Outperform Rating Jul 21, 2011 Analyst: Sequenom to Hire 20 Sales Reps for T21 Test by End of August Jun 22, 2011 CMS Seeks Stakeholder Input on Gene Test Reimbursement, Maintains Code Stacking for 2012 Premium Apr 5, 2011 Oppenheimer Revises Revenue Estimates for Life Technologies Mar 18, 2011 Oppenheimer Initiates Coverage of Complete Genomics with 'Outperform' Rating Breaking News Bio-Rad Laboratories Q2 Revenues Climb 33 Percent, Beat Estimates Veracyte Q2 Revenues More Than Double on Test Volume Spike Increased Testing Revenues Boost Opko Health Q2 Revenues 47 Percent Qiagen Q2 Revenues Grow 28 Percent CareDx Q2 Revenues Up 77 Percent Secondary Genetic Findings Often Requested if Given Second Chance, Study Finds The Scan Booster Push New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high. With Help from Mr. Fluffington, PurrhD Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic. Man Charged With Threatening to Harm Fauci, Collins The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials. Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.